An Australian medical cannabis company launched its hemp-based CBD teas – but you can’t buy them in Australia.

A little over a year ago we mentioned that Australia’s Creso Pharma Limited (ASX: CPH) announced that its hemp teas would be available in international markets in the third quarter of last year.

The teas are a little behind the original schedule, but are now available in Switzerland. There are three products in the second generation:

  • cannaQIX tea: Designed to relieve stress – CBD, vitamins and zinc.
  • cannaQIX NITE: As the name suggests, to support better sleep. Contains CBD and lemon balm.
  • cannaQIX immunity: CBD, vitamins, zinc, elderberry and ginger to “optimize well-being”.

The latter is a new product, not in the originally announced product range.

advertising

All three teas contain 5-10 mg of CBD (assumed: single dose) – so it’s a very low dose. The teas can be mixed with hot or cold water.

“We are proud to have completed the completion of this breakthrough technology for our new CBD tea products, which will open up a number of new and globally applicable opportunities for Creso Pharma,” said Dr. Gian Trepp, Director Commercial & Development.

But Australia is unlikely to be one of those options unless Creso shoots a Schedule 3 list as a drug (or change in law).

However, the company is keeping an eye on markets including Germany after a federal court ruled that previous charges against hemp tea sellers have been invalidated. The company also intends to distribute its hemp products in other European countries.

Creso uses the established cannaQix brand with its teas, a nutraceutical product line that also contains pastilles. Another new product on the boards is cannaQIX oral care, a lozenge product that “helps reduce stress and oral hygiene”. The lozenges contain 10 or 25 mg of essential oils from CBD, peppermint and sage.

In addition to products for humans, Creso Pharma manufactures feed supplements for animals under the “Anibidiol” brand.

In addition to hemp, the company also wants to try psychedelic treatments – specifically compounds in botanical psilocybin. better known as “magic mushrooms”. This would happen through the planned takeover of the Canadian company Halucenex Life Sciences Inc.